Desvaux, Emiko
Courteau, Alan
Bellaye, Pierre-Simon
Guillemin, Mélanie
Drouet, Camille
Walker, Paul
Collin, Bertrand
Decréau, Richard A.
Funding for this research was provided by:
Centre National de la Recherche Scientifique (1111)
Canceropôle Est (1111)
Fond Européen de Développement Régional (PO FEDER-FSE Bourgogne 2014/2020 Programs)
Agence Nationale de la Recherche (ANR-10-EQPX-05-01/IMAPPI Equipex)
Conseil Régional de Bourgogne (1111)
Cyclopharma (1111)
University of Burgundy (3MIM and PARI2 Programs (PHARMACOIMAGERIE ET AGENTS THERANOSTIQUES))
Article History
Received: 4 October 2018
Accepted: 3 December 2018
First Online: 20 December 2018
Ethics approval
: <i>Name of the institutions or licensing bodies that approved the experimental protocols</i>:<i>Nuclear safety</i> (a) Safety rules and protocols were set at and approved by the <i>Centre George-François Leclerc</i> (CGFL) and applied at CGFL Preclinical Imaging Platform; (b) The protocols strictly comply with the regulations governing radiopharmaceuticals and standards of the <i>French Nuclear Safety Agency</i> (ASN) that approves CGFL protocols.<i>In vivo studies</i> All animal studies were conducted at and approved by the Centre George François Leclerc (CGFL) in accordance with the relevant guidelines and legislation on the use of laboratory animals (directive 2010/63/EU) and were approved by accredited the <i>Ethical Committee</i> (C2ea Grand Campus n°105) and <i>French Ministry of Higher Education and Research</i>.
: Not applicable.
: The authors declare that they have no competing interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.